Literature DB >> 6252152

Cefotaxime in the treatment of pneumococcal pneumonia.

S G Jenkinson, M S Briggs, R D Bryn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6252152     DOI： 10.1093/jac/6.suppl_a.177

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  Third generation cephalosporins in the parenteral to oral switch.

Authors:  D Rimmer
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 2.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Respiratory superinfections after the use of third-generation cephem antibiotics.

Authors:  A Saito; K Mori; Y Shigeno; K Yamaguchi; K Hara
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Cefotaxime: efficacy and tolerance in lower respiratory tract infections caused by gram-positive cocci.

Authors:  H Lode; P D Glatzel
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 5.  Cefotaxime optimal dosage in adult patients. A reappraisal.

Authors:  A Simon; C A d'Aubrac; C Safran; C Carbon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.